Trials / Completed

CompletedNCT01174862

Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery

Comparative Cohort Study on the Outcome of Patients With Normal and Reduced Acetylsalicylic Acid Responsiveness Undergoing Coronary Artery Bypass Surgery

Status: Completed
Phase: —
Study type: Observational
Enrollment: 304 (actual)

Sponsor: University Hospital, Basel, Switzerland · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

In patients undergoing coronary artery bypass graft (CAGB) surgery, aspirin is commonly prescribed to prevent graft thrombosis and myocardial ischemia. However, there are still a significant number of grafts occluding in the postoperative period. This is partly attributed to reduced aspirin responsiveness, also called "aspirin resistance". At the moment, no standardized definition or laboratory test is available to quantify "aspirin resistance", and strong platelet reactivity in laboratory tests is not necessarily associated with increased thrombotic events. However, there is increasing evidence that reduced aspirin responsiveness in platelet function analyzers is associated with adverse long-term outcome and higher incidence of major adverse events in patients with stable coronary artery disease and in patients undergoing percutaneous coronary intervention. In patients undergoing coronary artery bypass graft surgery, the predictive value of a laboratory finding of reduced aspirin responsiveness remains unclear. Therefore, the aim of this study is to prospectively evaluate whether the pre- and/or postoperative laboratory finding of reduced aspirin responsiveness defined by MultiplateTM platelet function analyzer is associated with higher incidences of adverse outcome after 30 days and 12 months in patients undergoing CABG surgery.

Conditions

Timeline

Start date: 2010-06-01
Primary completion: 2012-06-01
Completion: 2013-06-01
First posted: 2010-08-04
Last updated: 2015-03-10

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01174862. Inclusion in this directory is not an endorsement.